Electra Therapeutics Raises $183M Series C to Fund Pivotal Rare Disease Trial

Why It Matters

The capital infusion enables Electra to advance its rare‑disease therapy toward regulatory approval, positioning the company for market entry and attracting further strategic partnerships in the biotech sector.

Deal Summary

Electra Therapeutics announced a $183 million Series C financing to support a newly launched pivotal trial for its rare disease candidate. The round was co-led by Nextech and EQT Life Sciences with participation from Sanofi, Mubadala Capital, OrbiMed, Blue Owl Capital and RA Capital Management.